Subscribe to our Newsletters !!
Using antibodies in different laboratory settings,
There are a few things to avoid while utilizing an
Sepsis is an overly amplified response of the body
TM Media is pleased to add the prestigious Elets 6
Alembic Pharmaceuticals Limited (Alembic) today an
It is important to understand that natural remedie
Dear Readers,Welcome to the latest issue of Microb
OmniBRx Biotechnologies Pvt Ltd, a pioneer in bioprocess engineering, is thrilled to announce its strategic collaboration with the Translational Health Science and Technology Institute (THSTI), an institute of Biotechnology Research and Innovation Council (BRIC), Department of Biotechnology, Ministry of Science and Technology, Govt of India. The aim of this alliance is to drive the implementation of new production technologies for lentiviral vectors (LVV) and CAR-T cells that can be used in cell and gene therapy manufacturing.
The combination between OmniBRx and THSTI will seek to utilize their individual strengths to create a new paradigm for regenerative medicine by merging proprietary Dynamic Bed Reactor (DBR) manufacturing technology with years of experience in cell-based therapies. This way, patients will have easier access to economic therapy options provided at shorter timespans.
“We are excited to partner with THSTI to push the boundaries of innovation in cell and gene therapy. This collaboration underscores our commitment to driving forward-thinking research and developing solutions that have a meaningful impact.”
— Mr. Ravindra Patel, MD & CTO of OmniBRx
“Our collaboration with OmniBRx is a pivotal step forward in THSTI’s mission to translate ground-breaking research into life-changing cell therapies that will significantly benefit the Indian population.”
— Prof. G Karthikeyan, Executive Director, THSTI
“This partnership marks a significant milestone in our journey to provide therapies that address unmet medical needs. THSTI has developed robust capabilities in clinical research and cutting-edge science, which, in partnership with OmniBRx, will be leveraged to develop cell therapies for the Indian population.”
— Dr. Amit Awasthi, Senior Professor, THSTI
OmniBRx Biotechnologies and THSTI will work together to drive the process of making cell and gene therapy accessible to larger population, both organizations are committed to achieve an outlined goals for delivering concrete results. In the coming months, more information on this collaboration’s progress will be shared.
It is India’s first bioprocess engineering company that has developed the single use bioreactor for mammalian cell lines which is aimed at providing advanced solutions and technological advancements. By emphasizing research and development, OmniBRx Biotechnologies aims to create transformative innovations that meet dynamic industry and societal needs.
THSTI is a globally acclaimed research institute under the Biotechnology Research and Innovation Council (BRIC), Department of Biotechnology, Govt. of India with extensive experience in clinical and translational research. With a focus on excellence and innovation, THSTI strives to transform the biotech sector through partnerships and path-breaking discoveries.
OmniBRx Biotechnologies Pvt Ltd Email: [email protected] Phone: +91-771-8843943
Translational Health Science and Technology Institute (THSTI) Email: [email protected] Phone: 0129-2876299
